Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Finished Goods (2017 - 2024)

China Pharma Holdings filings provide 8 years of Finished Goods readings, the most recent being $1.3 million for Q3 2024.

  • On a quarterly basis, Finished Goods rose 6.83% to $1.3 million in Q3 2024 year-over-year; TTM through Sep 2024 was $1.3 million, a 6.83% increase, with the full-year FY2023 number at $1.5 million, up 166.73% from a year prior.
  • Finished Goods hit $1.3 million in Q3 2024 for China Pharma Holdings, down from $1.5 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $1.7 million in Q1 2024 to a low of $551000.0 in Q4 2021.
  • Median Finished Goods over the past 5 years was $1.3 million (2022), compared with a mean of $1.2 million.
  • Biggest five-year swings in Finished Goods: crashed 46.0% in 2021 and later surged 166.73% in 2023.
  • China Pharma Holdings' Finished Goods stood at $960375.0 in 2020, then crashed by 42.63% to $551000.0 in 2021, then changed by 0.0% to $551000.0 in 2022, then soared by 166.73% to $1.5 million in 2023, then decreased by 11.91% to $1.3 million in 2024.
  • The last three reported values for Finished Goods were $1.3 million (Q3 2024), $1.5 million (Q2 2024), and $1.7 million (Q1 2024) per Business Quant data.